Impact of HIV-1 and Aging on Mucosal Vaccine Responses

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.

After being informed about the study and potential risks, patients will be screened to determine eligibility for the study and consented. Patients who meet eligibility requirements will be immunized with PCV 20. HIV-infected adults will be tested prior to and after vaccination by blood, nasal filter paper, and stool samples to characterize mucosal and systemic antibody responses . HIV-uninfected control adults will be tested at vaccination and post vaccination to characterize mucosal and systemic antibody responses .

Inclusion Criteria:

• Veterans only (accessibility to non-veterans pending)
• Age 21-45 or 55-75 Years Old
• Have not received pneumococcal vaccine Prevnar PCV-13
• Able to attend 2-3 study visits over 1 month

HIV+:

-Undetectable Viral load

HIV negative controls:

-no history or risks for HIV infection

Exclusion Criteria:

• Spleen removed
• Chronic Kidney disease (creatinine ≥ 2.0 mg/dL)
• Active liver disease
• Currently taking: Corticosteroids (prednisone, medrol, etc), Chemotherapy, Immunosuppressive medication (cyclosporine, methotrexate, azathioprine, infliximab, adalimumab, rituximab, etanercept, etc), or illicit drugs (methamphetamine, cocaine, crack, or heroin)